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Abstract
!
In our previous study, we reported the interesting
in vitro antiplasmodial activity of some Rwandan
plant extracts. This gave rise to the need for these
extracts to also be evaluated in vivo and to identi-
fy the compounds responsible for their antiplas-
modial activity. The aim of our study was, on the
one hand, to evaluate the antiplasmodial activity
in vivo and the safety of the selected Rwandan
medicinal plants used in the treatment of malaria,
with the objective of promoting the development
of improved traditional medicines and, on the
other hand, to identify the active ingredients in
the plants. Plant extracts were selected according
to their selectivity index. The in vivo antiplasmo-
dial activity of aqueous, methanolic, and dichloro-
methane extracts was then evaluated using the
classical 4-day suppressive test on Plasmodium
berghei infectedmice. The activity of the plant ex-
tracts was estimated by measuring the percent-
age of parasitemia reduction, and the survival of
the experimental animals was recorded. A bio-
guided fractionation was performed for the most
promising plants, in terms of antiplasmodial ac-
tivity, in order to isolate active compounds identi-
fied by means of spectroscopic and spectrometric
methods. The highest level of antiplasmodial ac-
tivity was observed with the methanolic extract
of Fuerstia africana (> 70%) on days 4 and 7 post-
treatment after intraperitoneal injection and on
day 7 using oral administration. After oral admin-
istration, the level of parasitemia reduction ob-
served on day 4 post-infection was 44% and 37%
with the aqueous extract of Terminalia mollis and
Zanthoxylum chalybeum, respectively. However,
the Z. chalybeum extract presented a high level of
toxicity after intraperitoneal injection, with no
animals surviving on day 1 post-treatment. F. afri-
cana, on the other hand, was safer with 40%
mouse survival on day 20 post-treatment. Ferru-
ginol is already known as the active ingredient in
F. Africana, and ellagic acid (IC50 = 175 ng/mL) and
nitidine (IC50 = 77.5 ng/mL) were identified as the
main active constituents of T. mollis and Z. chaly-
beum, respectively. F. africana presented very
promising antiplasmodial activity in vivo.
Although most of the plants tested showed some
level of antiplasmodial activity, some of these
plants may be toxic. This study revealed for the
first time the role of ellagic acid and nitidine as
the main antimalarial compounds in T. mollis and
Z. chalybeum, respectively.
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Malaria remains a major public health problem,
especially in subtropical regions. In 2010, approx-
imately 3.3 billion people worldwide were ex-
posed tomalaria. The highest risk is in the sub-Sa-
haran Africa regions where approximately 81% of
cases and 91% of deaths occurred in that year,
mostly in children under five years of age and in
pregnant women [1]. The rise and spread of the
resistance of Plasmodium falciparum malaria tota Med 2014; 80: 482–489chloroquine and sulfadoxine-pyrimethamine, [2]
as well as the resistance of falciparum malaria
vectors to pyrethroids (insecticides used to pre-
vent malaria in endemic regions), presents a seri-
ous challenge, especially in developing countries
such as Rwanda [1]. It is therefore imperative that
new antimalarial drugs be designed. Medicinal
plants constitute a promising source of new drugs
and there is nowa real interest worldwide in anti-
plasmodial plants [3]. Many plant extracts have
exhibited early promising antiplasmodial activity
Fig. 1 Parasitemia reduction (%) of methanol and
aqueous plant extracts in mice infected by P. ber-
ghei. Results of in vivo testing on parasitemia reduc-
tion in mice infected by P. berghei. PEG (polyethyl-
ene glycol) and normal saline were used as the
negative control and chloroquine 4mg/kg as the
positive control. Mice (n = 5) received 300mg/kg of
methanolic orally and an aqueous extract of T. mollis
(root bark) and Z. chalybeum (root bark), and a
methanolic extract of F. africana (leaf and stem),
separately for four days. The percentage of parasit-
emia reduction indicated at the top of each column
was calculated for each plant sample versus the
parasitemia in the control group taken as 100%. FA,
F. africana; TM, T. mollis; ZC, Z. chalybeum.
Table 1 Viability of mice infected
by P. berghei after treatment with
plant extracts via oral and intraper-
itoneal administration. The num-
ber of dead mice was recorded
daily in all study groups to deter-
mine the average survival time of
the infected mice after treatment.





F. africana (L & S) Methanol extract 11.8 ± 6.7 17.6 ± 1.2
T. mollis (RB) Methanol extract 7.8 ± 0.4 6.2 ± 7.4
Aqueous extract 8.2 ± 6.1 nd
Aqueous extract free of tannins nd 9.2 ± 3.9
Z. chalybeum (RB) Methanol extract 14.2 ± 6.0 0
Aqueous extract 10.6 ± 5.3 nd
PEG nd 10. 5 ± 5.7 nd
NaCl 0.9% nd nd 13 ± 8
Chloroquine nd > 20 > 20





























l.in vitro and they may or may not prove to be more active in vivo.
In our previous report, some medicinal plants used in Rwanda to
treat malaria showed interesting antiplasmodial activity in vitro
[4]. However, before those plants can be recommended in the
treatment of malaria, their activity and safety needs to be eval-
uated in vivo. To this end, in the present study, three plants, Fuer-
stia africana T.C.E. Fries (Lamiaceae), Terminalia mollis M.A.
Lawson (Combretaceae), and Zanthoxylum chalybeum Engl. (Ru-
taceae), were selected for in vivo antiplasmodial testing based
on their antiplasmodial and cytotoxic activity. These plants are
traditionally used in many countries and the antiplasmodial ac-
tivity of other Fuerstia, Terminalia, and Zanthoxylum species is al-
ready well known [5–8]. Determination of the active ingredient
responsible for the antiplasmodial activity of these plants consti-
tutes an important step before they may be recommended in the
treatment of malaria. As F. africana has already been widely
studied and its active compounds already isolated, we decided
to focus our bioguided fractionation on the two other plants of
interest, Z. chalybeum and T. mollis. These two plant species were
submitted to a phytochemical study in order to isolate and iden-
tify their antimalarial compounds. The present study reports the
in vivo antiplasmodial activity of F. africana, T. mollis, and Z. cha-
lybeum against Plasmodium berghei inmice and the identification
of the active ingredients responsible for the antiplasmodial activ-
ity of the last two of these plant species.Results
!
In our previous report [4], some plant extracts exhibited an inter-
esting level of antiplasmodial activity in vitro with an IC50
< 15 µg/mL. The cytotoxic activity of those plant samples was
then evaluated and the selectivity index determined. Based on
their selectivity index, three plant extracts, methanol, leaf, and
stem extract of F. africana, and the methanolic root bark extract
of Z. chalybeum and T. mollis were selected for in vivo testing us-
ing oral and intraperitoneal administration. Of the extracts ad-
ministered via the oral route, on day 4 post-treatment, the meth-
anolic extract of Z. chalybeum exhibited the best parasitemia re-
duction (37%) followed by the methanolic extract of F. africana
(25%). On day 7, the highest level of parasitemia reduction was
obtained with the methanolic extract of F. africana (70%) fol-
lowed by the methanolic extract of T. mollis (45%) (l" Fig. 1). Of
the extracts administered via the intraperitoneal route, only the
F. africana extract gave good results, with a parasitemia reduc-
tion level of 74% and 71% on days 4 and 7, respectively. On the
other hand, mice that received Z. chalybeum did not survive for
more than one day post-treatment (l" Table 1).
The antiplasmodial activity of F. africana is already known. A pre-
vious study reported the in vitro antiplasmodial and cytotoxic ac-
tivity of ferruginol, the active ingredient in F. africana [5]. How-
ever, results showed that the plant presented a good mouse sur-
vival time, indicating that ferruginol toxicity in themousemay be
weak. Other constituents of F. africanamay also modulate its ac-
tivity. Considering that the antiplasmodial compound of F. africa-
na has already been identified and is known to be cytotoxic, we
decided not to study the phytochemistry of this plant, but to in-Muganga R et al. In Vitro and… Planta Med 2014; 80: 482–489
Table 2 Percentage of hemolysis
with T. mollis and Z. chalybeum root
bark extracts.
Sample Hemolysis (%)
100 µg/mL 200 µg/mL
T. mollis crudemethanol extract 0.05 ± 0.03 0.11 ± 0. 40
T. mollis crude aqueous extract 0.08 ± 0.06 0.03 ± 0.02
Z. chalybeum crudemethanol extract 0.17 ± 0.15 0.39 ± 0.04
Table 3 In vitro antiplasmodial
activity (IC50 values) of T. mollis
and Z. chalybeum root bark ex-
tracts, fractions, and isolated com-
pounds on two P. falciparum
strains. Data are expressed as
mean ± SD, n ≥ 3.
Plant sample 3D7 (IC50 µg/mL) F32 (IC50 µg/mL)
T. mollis crudemethanolic extract 3.84 ± 1.23 3.42 ± 0.77
T. mollis crude aqueous extract 4.66 ± 0.89 12.31 ± 1.18
T. mollis aqueous extract free of tannins (TMFT) 25.77 ± 4.89 nd
T. mollis ethyl acetate fraction (TMEA) 2.10 ± 0.48 nd
T. mollis aqueous fraction (TMA) 19.72 ± 4.86 nd
T. mollis precipitate fraction (TMP) 39.71 ± 2.18 nd
T. mollis A1 > 50 nd
T. mollis A2 fraction from TMEA (impure ellagic acid) 0.75 ± 0.06 nd
T. mollis A3 from TMEA (ellagic acid) 0.17 ± 0.17 0.12 ± 0.08
T. mollis A4 fraction from TMEA (punicalagins) > 50 > 50
Z. chalybeum crudemethanolic extract 6.18 ± 1.23 nd
Z. chalybeum ZD2 fraction (CH2Cl2 fraction) 4.81 ± 0.26 nd
Z. chalybeum ZA2 fraction (aqueous fraction) 14.37 ± 5.49 nd
Z. chalybeum ZP fraction (precipitate) from ZD2 22.53 ± 2.37 nd
Methyl canadine 2.01 ± 1.10 nd
Z. chalybeum F7 fraction (nitidine) 0.07774 ± 0.01 0.027 ± 0.013
Chelerythine 1.35 ± 0.80 nd
Tembetarin 2.01 ± 0.74 nd
Artemisinin 0.0052 ± 0.0002 0.0030 ± 0.0003






























l.stead focus the remainder of the present study on the other two
plants, Z. chalybeum and T. mollis.
As methanol extracts of Z. chalybeum and T. mollis did not exhibit
a high level of activity in vivo and taking into consideration the
fact that traditional healers use water as the solvent in the prep-
aration of these plants, the aqueous extracts of T. mollis and Z.
chalybeum, active in vitro, were also assessed for their in vivo
antiplasmodial activity (per oral administration). On day 4, the
activity of the aqueous and methanolic extracts of Z. chalybeum
was quite similar (parasitemia reduction of 34 and 37%, respec-
tively), whereas the aqueous extract of T. mollis was more active
(44%) than the methanolic extract (5%) (l" Fig. 1, Table 1). Meth-
anolic root bark extracts of T. mollis and Z. chalybeum have been
shown to present a reasonable level of antiplasmodial activity in
vitro (IC50 < 15 µg/mL) [4]. However, in this present study, these
extracts were found to be less active in vivo, suggesting that the
oral absorption of active ingredients from those plants may be
poor.
The in vitro hemolysis test was done only on two plants, Z. chaly-
beum and T. mollis. The percentage of hemolysis was found to be
0.05 and 0.08, respectively, for the methanolic and aqueous root
bark extracts of T. mollis at a concentration of 100 µg/mL. The lev-
el of hemolysis was 0.11% and 0.03% for the same extracts at a
concentration of 200 µg/mL. The methanol root bark extract of Z.
chalybeum exhibited a percentage of hemolysis of 0.17 and 0.39
at a concentration of 100 and 200 µg/mL, respectively (l" Table 2).
All the tested T. mollis root bark extracts showed antiplasmodial
activity in vitro and the best activity was found with the metha-
nolic extract, which was chosen for the bioguided fractionation.
After liquid-liquid partition, the ethyl acetate fraction (TMEA)
was found to be more active (IC50 = 2.10 µg/mL) than the aqueousMuganga R et al. In Vitro and… Planta Med 2014; 80: 482–489and insoluble fractions (IC50 = 4.66 µg/mL and 39.71 µg/mL, re-
spectively). The fractionation of TMEA yielded different fractions
from which compound A3 was isolated (fraction: 87–88). This
compound presented a very high level of activity, with an
IC50 = 0.175 µg/mL (l" Table 3). Fraction A2 also presented a very
significant level of activity (IC50 = 0.75 µg/mL) and its further
analysis revealed that it was a semi-pure fraction containing ad-
ditional A3 (l" Table 3). The spectral data of all the isolated con-
stituents were compared with their corresponding references.
Compound A1 was identified as an ellagic acid derivative and
was found to be inactive against P. falciparum strain 3D7. Com-
pound A3, found to be very active against P. falciparum, was iden-
tified as ellagic acid with a purity of 98% (l" Fig. 2). Fraction A4
was identified as a mixture of punicalagin A & B (anomeric iso-
mers) by comparing their spectral data with those of a commer-
cial sample (l" Fig. 3). The commercial sample was a mixture of
punicalagin A (38.1%) and punicalagin B (61.1%). Gallic acid and
some condensed tannins, such as catechin, gallocatechin, and ep-
igallocatechin, also present in T. mollis, were found to have a low-
er level of antiplasmodial activity, (IC50 > 25 µg/mL) than the one
found for ellagic acid [8]. Consequently, ellagic acid can be identi-
fied as the main antiplasmodial constituent with the other com-
pounds present in T. mollis and possibly serves to reinforce its
antiplasmodial activity.
For Z. chalybeum, after alkalinization and extraction of the aque-
ous fraction by dichloromethane, the best antiplasmodial activity
was obtained with the organic fraction ZD2 (IC50 = 4.8 ± 0.26 µg/
mL). A bioguided preparative HPLC of this organic fraction
yielded different fractions, of which fraction 7 (F7), a yellow nee-
dle-like crystal, was found to be the most active, with
IC50s = 77.74 and 27 ng/mL, respectively, on the P. falciparum
Fig. 2 Chemical struc-
ture of ellagic acid.
485Original Papersstrains 3D7 and F32. Based on NMR andmass spectrometry spec-
tra, the active compoundwas identified as nitidine (l" Fig. 4). The
yield of nitidine isolated from the root bark of Z. chalybeum was
estimated to be 0.002% and its purity around 96.53%. Methyl can-
adine, chelerythine, and tembetarin were also isolated from the
plant and were found to exhibit an IC50 > 1 µg/mL (l" Table 3).Fig. 4 Chemical struc-
ture of nitidine.






























The aqueous crude extract of T. mollis exhibited a high level of
antiplasmodial activity (IC50 = 4.66 µg/mL) against P. falciparum
strain 3D7, supporting the use of this plant in traditional medi-
cine. However, a previous study reported a weak level of activity
of the aqueous extract from this plant [4]. This difference may be
explained by the fact that the samples used in the two studies
were different. Furthermore, a significant difference in terms of
activity was observed here between samples of T. mollis collected
during the summer period and those collected during the rainy
season. It has already been observed that the time of collection
and the locality of the plant material may play a major role in its
beneficial properties [4].
Concerning in vivo activity, themajority of themice treated intra-
peritoneally with T. mollis extract died on day 2 post-treatment
and only one mouse survived until day 20 post-treatment, sug-
gesting that the plant extract is toxic in mice. The survival time
for mice treated orally with the methanol or water extract was
also lower than for the control mice, indicating, again, a potential
toxicity. However, on day 4 post-infection, the mice treated orally
with T. mollis exhibited a significant decrease in their parasite-
mia, indicating a verifiable activity against the parasite. The tox-
icity of Terminalia species has been previously reported and may
be attributed to saponins [9] or to hydrolysable tannins [10]. We
therefore wanted to verify whether hydrolysable tannins present
in T. mollis, such as punicalagin and its derivatives, were respon-
sible for this toxicity. For this purpose, a methanolic extract free
of hydrolysable tannins was made using a size exclusion column
(Sephadex) and was then administered intraperitoneally to mice.
The majority of the mice (60%) treated with this preparation free
of hydrolysable tannins died within 6 days after infection, mean-
ing that other constituents may contribute to the toxicity of the
plant. Moreover, a condensed tannin called terminalin (MW=
603) isolated from T. oblongata has been reported to be toxic
[11] and this toxic compoundmay also be present in other Termi-
nalia species such as T. mollis. Unfortunately, we were not able to
verify the presence of this toxic condensed tannin in our prepara-
tion, as the compound is not commercialized and we could not
identify it in the extract. The reason why the toxicity of the plant
was previously attributed to its saponin content [9] is that sapo-
nins have a deleterious hemolyzing effect on circulating red
blood cells [12].
However, in the present study, hemolysis testing carried out on
aqueous and methanolic extracts of T. mollis at a concentration
of 200 µg/mL revealed no hemolytic effect from the extracts
(l" Table 2). This indicates that at the concentrations presenting
antiplasmodial activity, extracts of T. mollis exhibited no toxicity
towards erythrocytes, suggesting that at a therapeutic dose level,
no toxicity of the plant caused by its saponins is to be expected.
Furthermore, after oral administration of 300mg/kg methanolic
root bark extract of T. mollis per day for 3 days, no acute toxicity
was observed in uninfectedmice. This means that malaria caused
by P. berghei in mice negatively influences mouse survival time.Bioguided fractionation led to the identification of ellagic acid as
an active compound (IC50 = 0.175 µg/mL), while ellagic acid deriv-
atives were inactive. These results support previous reports in
which the important role of free hydroxyl groups in the antiplas-
modial activity of ellagic acidwas observed [13]. The in vitro anti-
plasmodial activity of ellagic acid is already known [14] and our
results are in accordance with those already found (IC50 between
90 and 175 ng/mL). In this study, ellagic acidwas found inT. mollis
root bark in an aglycone form (free form). Most of the time, ellagic
acid is present in a conjugated form with a glycoside moiety, and
it is uncommon for it to be found in its free form in nature [15].
Fraction A4, the mixture of punicalagin A & B, did not present
any interesting antiplasmodial activity in either of the P. falcipa-
rum strains. In contrast, previous studies have reported the anti-
plasmodial activity of punicalagin, although without specifying
which form (punicalagin A or B), was the active constituent [16].





























l.rum strain 3D7 (IC50 = 27.73 µg/mL) [17]. This level of punicalagin
activity is very low for a pure compound and should be qualified
as negligible compared to that found for other pure compounds
such as ellagic acid. Punicalagin is a hydrolysable polyphenolic
compound [18] found in plants. Commonly called ellagitanin, pu-
nicalagin plays the physiological role of protection against micro-
bial decay [19]. Various biological activities of punicalagin have
been reported: antioxidant, anti-inflammatory, anti-genotoxic,
antiviral [20–22], and hepatoprotective [23]. However, there has
been a great deal of discussion about the toxicity of this com-
pound, as it may provoke liver necrosis and nephrotoxicity [11,
24,25]. Further studies are needed to prove the safety of punica-
lagin in humans. In the present study, the crude aqueous extract
free of tannin was also found to be active, suggesting that the ac-
tive ingredient(s) is/are not totally adsorbed by hide powder.
HPLC analysis of this extract demonstrated that ellagic acid was
still present, whereas punicalagin and its analogs were almost
absent.
Ellagic acid has been shown to present synergistic activity with
other antimalarial drugs, such as chloroquine, atovaquone, me-
floquine, and artesunate, and a slight antagonism against arte-
misinin [14]. Themechanism of action of ellagic acid on P. falcipa-
rum is not very well known. Some researchers have suggested
that since ellagic acid has the ability to form a π-π complex [26],
it may act at the mature trophozoite and young schizont stage of
the erythrocytic life cycle by inhibiting β-hematin formation in
the parasite in the same way as aminoquinoline antimalarial
agents such as chloroquine [27]. Although ellagic acid is very ac-
tive against malaria, its bioavailability is low. Indeed, ellagic acid
exhibits poor absorption (less than 1%) and is rapidly excreted
after oral administration [28]. This may explain why, in the
present study, the percentage of inhibition of the plant extract
in the in vivo test using oral administration was not extremely
high. Ellagic acid possesses other beneficial properties, such as
anticancer, antimutagenic [29,30], antioxidant, anti-inflamma-
tory [14,31], antiviral [32], and antibacterial activity [19]. The
fact that this compound presents antiplasmodial, antioxidant,
and anti-inflammatory activity may be an advantage, especially
in cases of malaria [33]. Ellagic acid also exhibits cardioprotective
activity [34], antiulcer activity [35], and hepatoprotective activity
[36]. Moreover, since part of the P. falciparum life cycle occurs in
the liver, the hepatoprotective activity of ellagic acid is a real ad-
vantage. Nevertheless, galenical or chemical modifications are
needed to improve its activity after oral administration.
All mice that received the methanolic root bark extract of Z. cha-
lybeum died within 5–10 minutes after intraperitoneal injection,
indicating the high toxicity of the extract in mice. The toxicity of
Z. chalybeum may result from its quaternary alkaloids [37], in
particular candicine, which has already been reported to have a
prominent curariform effect, stimulating nicotinic and paralyzing
nicotinic actions [38]. Furthermore, just before sudden death, the
mice in the present study exhibited convulsions and paralysis,
and those symptoms have already been observed in mice after
an intra-peritoneal injection of candicine [39]. As for T. mollis,
no hemolysis was observed in the present study on erythrocytes
with the highest concentrations tested for antiplasmodial activ-
ity.
As Z. chalybeum is rich in alkaloids that may contribute to its var-
ious therapeutic properties [37], the bioguided fractionation was
performed here only on targeted alkaloids. Of all the alkaloids
isolated, nitidine exhibited the highest level of antiplasmodial ac-
tivity (IC50 = 0.075 µg/mL). Nitidine is a quaternary alkaloid al-Muganga R et al. In Vitro and… Planta Med 2014; 80: 482–489ready known to be present in Z. chalybeum and in the Rutaceae
family in general [40–42]. Nitidine was isolated for the first time
in Z. nitidium and the compound is responsible for the antiplas-
modial activity of many antimalarial remedies [43,44]. A pre-
vious study reported that the yield of nitidine from the root of Z.
chalybeumwas about 0.0123% [45]. This yield is higher than that
found in the root bark (0.002%) in the present study, suggesting
that the whole root of the plant contains more nitidine. This also
explains why the root of the plant without the bark has also been
found to be active against P. falciparum (IC50 = 7.31 µg/mL) (data
not published). Considered to be a potential anticancer drug, niti-
dine has been reported to have other therapeutic properties such
as antileukemic [40], antimicrobial, anti-inflammatory, analgesic,
and anti-HIV [46] activity. In our study, the high level of antiplas-
modial activity of nitidine on chloroquine-sensitive P. falciparum
strains was in accordance with previously reported findings [43,
44]. The slight differences between the IC50 values found in our
study in comparison with previous findings may be explained
by the fact that different methods were used. In the previous
studies, other alkaloids such as methyl canadine, chelerythine,
and tembetarin were also isolated from the plant but their activ-
ity was shown to be much lower (IC50 > 1 µg/mL) compared to
that of nitidine. Consequently, nitidine could be considered the
main antiplasmodial ingredient in Z. chalybeum and the other al-
kaloids, such as chelerythine and methyl canadine, which are al-
ready known in the plant [37] andmay intervene by synergism in
this activity. Nitidine has already been reported to be the active
ingredient in another Zanthoxylum species, Z. gilletii [47]. The
mechanism of action of nitidinemay be due to its ability to inhib-
it topoisomerase in malaria parasites [43]. However, it has re-
cently been reported that nitidine may possess a chloroquine-
like mechanism of action because of its capacity to bind to heme
and to inhibit β-hematin formation [44]. Further investigations
regarding nitidine would still be of interest in order to exploit
the remarkable antiplasmodial activity of this compound.Materials and Methods
!
Plant material
Samples of T. mollis and Z. chalybeumwere collected between Au-
gust and October 2010 from Akagera National Park (South-West
Rwanda), whereas the sample of F. africana was collected in the
same period but from Huye (Southern Province of Rwanda). Each
species was identified Dr. Bizuru Elias (Senior Lecturer, Depart-
ment of Biology, University of Rwanda) and confirmed by Profes-
sor Elmar Robbrecht (Botanist of National Botanic Garden of Bel-
gium). A voucher specimen was deposited in the Rwandan Na-
tional Herbarium at Butare and another at the National Botanic
Garden of Belgium at Meise. The voucher numbers are
BR0000005087266, BR0000005087167, and BR0000005088850
for Z. chalybeum, T. mollisi, and F. africana, respectively. All sam-
ples collected were air-dried at room temperature with no direct
sunlight for 3 days. Dried plant samples were then pulverized us-
ing an electrical grinder under strict hygienic conditions.
Preparation of plant extracts for in vivo testing
Crude methanolic and aqueous plant extracts were prepared as
described early [4] and then dissolved in polyethylene glycol
(PEG), normal saline (NaCl 0.9%), or a mixture of 7% Tween 80
and 3% ethanol according to their solubility. The last solvent was





























l.In vitro hemolysis with plant extracts
Methanolic and aqueous root bark extracts of T. mollis and Z. cha-
lybeum at a final concentration of 200 and 100 µg/mL in DMSO
(1%) were tested with 10% freshly heparinized human blood (A
+) in PBS. 190 µL of 10% human blood were added to 10 µL of
plant extract and the mixture was incubated for 1 h under con-
stant and slow shaking at room temperature. After incubation,
the solutions were centrifuged for 5min at 2000 rpm in an Ep-
pendorf centrifuge 5417 R. The supernatant was removed and
the absorbance (A) of liberated hemoglobin was measured at
550 nm with a Perkin Elmer Wallac Victor2 spectrophotometer.
DMSO (20%) (Sigma-Aldrich), Triton − 100 (20%), and PBS (Lonza)
were used, respectively, as the solvent, positive (100% hemoly-
sis), and negative control. Each sample was analyzed in triplicate
and the mean ± SE was calculated. The percentage of hemolysis
was calculated as follows:
% Hemolysis: [(A product – A solvent) / (A Triton – A PBS)] × 100
In vivo antiplasmodial activity
Permission and approval were obtained for the present study
from the University of Liège Ethics Committee on March 19,
2012 (case file number 721). All mice used were SPF (specific
pathogen free) females, approximately 4–5 weeks old (18–20 g),
and free from Eperythrozoon coccoides and Haemobartonella mu-
ris. The mice were obtained from Charles River (France). The par-
asite used to infect the mice was P. berghei, NK173 strain. In vivo
antiplasmodial tests were performed based on the classical 4-day
suppressive test as previously reported [48]. Briefly, female Swiss
mice (5mice/group) were infected by P. bergheiNK173 four hours
before treatment. Treatment doses (200 and 300mg/kg of plant
extract) were given intraperitoneally and orally once daily from
day 0 to day 3. On days 4 and 7, thin mouse tail blood smears
were prepared and stained with Giemsa. Parasitemia was deter-
mined by counting at least 500 erythrocytes under a microscope.
Chloroquine diphosphate (Sigma, purity ≥ 98%) at 4mg/kg doses
and physiological serum (To) or PEG were used as the positive
control and negative control, respectively. The percentage of par-
asitemia reduction (activity) was calculated on days 4 and 7 using
the following formula [48]:
%Inhibition ¼ 100 fMean parasitemia treated
Mean parasitemia control
 100g
Isolation and identification of antiplasmodial
compounds
In our previous report, the highest level of antiplasmodial activity
in T. molliswas found usingmethanol extract [4], which was then
fractionated to isolate active constituents. The crude methanolic
root bark extract was obtained by macerating 500 g of the plant
material with 6 L of methanol for 72 hours at room temperature.
Extracts were then evaporated to dryness under reduced pres-
sure and the yieldwas 38.29%. An aliquot (50 g) of themethanolic
extract was solubilized in a 150-mL mixture of methanol and
water (8 :2) and then consecutively extracted with ethyl acetate
andwater (150mL×3). Three fractions were then obtained, TMEA
(± 48%), an aqueous fraction (TMA) (± 38%), and a precipitate
(TMP) (± 14%). Fractions were tested for antimalarial activity
and the most active fraction was fractionated by preparative
high-performance liquid chromatography (HPLC) (Agilent Tech-
nologies 1200 series), size exclusion (Fractogel® TSK HW-40 (s)
(Merck), and Sephadex® (Sigma-Aldrich) in order to isolate purecompounds, which were also tested. HPLC (reversed phase) was
performed using acetonitrile-pure water as the mobile phase in
gradient mode and an ODS C18 column Hypersil 250/4.6mm
(5 µm; Alltech) as the stationary phase. Methanol was used to
separate the compounds with Fractogel, while ethanol and pure
water were used as the eluents for Sephadex. Fractogel was used
to obtain an aqueous fraction free of tannins (TMFT), which was
used in in vitro and in vivo antiplasmodial tests. Sephadex was
used to isolate compounds A1, A3, and fractions A2, A4. Pure
compounds were further submitted to NMR and mass spectros-
copy in order to determine their chemical structure.
Similarly, the best antiplasmodial activity for Z. chalybeum was
obtained with the methanolic root bark extract, fromwhich pure
compounds were isolated. The powdered root bark of Z. chaly-
beum (500 g) was extracted with 6 L of a mixture of methanol
and acetic acid (1%) for 72 hours at room temperature. The solu-
tion obtained was concentrated to about 500mL and pure water
(± 200ml) was added to precipitate pigments. After filtration, the
solution was then extracted with dichloromethane to obtain two
phases. The aqueous phase (ZA1) was basified by sodium carbon-
ate (pH 10) and then extractedwith dichloromethane. Three frac-
tions were obtained: aqueous fraction (ZA2), organic fraction
(ZD2), and an insoluble fraction (ZP), which were subsequently
submitted to in vitro antiplasmodial testing. Themost active frac-
tion was fractionated using preparative HPLC with acetonitrile
and trifluoroacetic acid 0.05% as the mobile phase in gradient
mode and a Pursuit 5 Diphenyl SS 250 × 4.6mm, (5 µm) (Varian)
as the stationary phase. Isolated pure compounds were tested in
vitro and their chemical structure was determined using NMR
(Bruker Avance 500MHz DRX 500 spectrometer) and mass spec-
trometry (Micromass ESI‑Q‑TOF II instrument). The aqueous
fractionwas acidified and quaternary alkaloids were precipitated
overnight with Mayerʼs reagent. The next day, the precipitate was
rinsed with cold water and then eluted with a mixture of ace-
tone-water-ethanol (6 :1:2) on an ion exchange resin column
(Amberlite®), which transforms alkaloids into their chloride form.
The alkaloid fraction obtained was further fractionated using
preparative HPLC, and isolated pure quaternary alkaloids were
identified as described above.
Antiplasmodial activity of fractions and
pure compounds
Crude methanolic, aqueous extracts, and different fractions of
the plant were submitted to in vitro antiplasmodial testing
against two P. falciparum strains, 3D7 and F32. The P. falciparum
strain F32 was chosen because it originates from Tanzania, a
country close to Rwanda, where the plant is used to treat malaria.
A parasite culture was carried out as already described [49] and
an antiplasmodial activity test was performed according to the
method previously reported [4]. Artemisinin (98% Sigma-Al-
drich) and chloroquine (Sigma-Aldrich) were used as references.
All samples were tested in triplicate and the results are expressed
as mean ± SD.
Supporting information
HPLC analysis of T. mollis and Z. chalybeum, and nuclear magnetic
resonance spectra of ellagic acid and nitidine in DMSO are avail-
able as Supporting Information.Muganga R et al. In Vitro and… Planta Med 2014; 80: 482–489
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